Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belzutifan + lenvatinib
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Belzutifan + lenvatinib is a combination of two oral small molecule drugs: **belzutifan**, a hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor, and **lenvatinib**, a receptor tyrosine kinase inhibitor that targets multiple kinases involved in tumor angiogenesis, proliferation, and cancer progression. This combination is being investigated for the treatment of advanced clear cell renal cell carcinoma (ccRCC), particularly in patients whose disease has progressed following treatment with PD-1/L1 inhibitors and VEGF tyrosine kinase inhibitors. Belzutifan inhibits HIF-2α, impairing cellular hypoxia response and blocking downstream genes involved in growth and angiogenesis. Lenvatinib inhibits VEGF receptors (VEGFR1-3), FGFR1-4, PDGFRα, KIT, and RET, disrupting angiogenic and proliferative signaling. Clinical trials have demonstrated promising antitumor activity and manageable safety with this combination in ccRCC patients[1][3][5].
- Brand names
- WeliregLenvima
- Other names
- belzutifan + lenvatinib
02
Targets
EPAS1 (Hypoxia-inducible factor 2-alpha)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR3 (Fibroblast growth factor receptor 3)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on belzutifan + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belzutifan + lenvatinib.